BACKGROUND: Family history of venous thromboembolism (VTE) has been suggested to be more useful in risk assessment than thrombophilia testing. OBJECTIVES: We investigated established genetic susceptibility variants for association with VTE and evaluated a genetic risk score in isolation and combined with known trigger factors, including family history of VTE. PATIENTS/ METHOD: A total of 18 single nucleotide polymorphisms (SNPs) selected from the literature were genotyped in 2835 women participating in a Swedish nationwide case-control study (the ThromboEmbolism Hormone Study [TEHS]). Association with VTE was assessed by odds ratios (ORs) with 95% confidence interval (CI) using logistic regression. Clinical and genetic predictors that contributed significantly to the fit of the logistic regression model were included in the prediction models. SNP-SNP interactions were investigated and incorporated into the models if found significant. Risk scores were evaluated by calculating the area under the receiver-operating characteristics curve (AUC). RESULTS: Seven SNPs (F5 rs6025, F2 rs1799963, ABO rs514659, FGG rs2066865, F11 rs2289252, PROC rs1799810 and KNG1 rs710446) with four SNP-SNP interactions contributed to the genetic risk score for VTE, with an AUC of 0.66 (95% CI, 0.64-0.68). After adding clinical risk factors, which included family history of VTE, the AUC reached 0.84 (95% CI, 0.82-0.85). The goodness of fit of the genetic and combined scores improved when significant SNP-SNP interaction terms were included. CONCLUSION: Prediction of VTE in high-risk individuals was more accurate when a combination of clinical and genetic predictors with SNP-SNP interactions was included in a risk score.
BACKGROUND: Family history of venous thromboembolism (VTE) has been suggested to be more useful in risk assessment than thrombophilia testing. OBJECTIVES: We investigated established genetic susceptibility variants for association with VTE and evaluated a genetic risk score in isolation and combined with known trigger factors, including family history of VTE. PATIENTS/ METHOD: A total of 18 single nucleotide polymorphisms (SNPs) selected from the literature were genotyped in 2835 women participating in a Swedish nationwide case-control study (the ThromboEmbolism Hormone Study [TEHS]). Association with VTE was assessed by odds ratios (ORs) with 95% confidence interval (CI) using logistic regression. Clinical and genetic predictors that contributed significantly to the fit of the logistic regression model were included in the prediction models. SNP-SNP interactions were investigated and incorporated into the models if found significant. Risk scores were evaluated by calculating the area under the receiver-operating characteristics curve (AUC). RESULTS: Seven SNPs (F5 rs6025, F2 rs1799963, ABO rs514659, FGGrs2066865, F11 rs2289252, PROC rs1799810 and KNG1rs710446) with four SNP-SNP interactions contributed to the genetic risk score for VTE, with an AUC of 0.66 (95% CI, 0.64-0.68). After adding clinical risk factors, which included family history of VTE, the AUC reached 0.84 (95% CI, 0.82-0.85). The goodness of fit of the genetic and combined scores improved when significant SNP-SNP interaction terms were included. CONCLUSION: Prediction of VTE in high-risk individuals was more accurate when a combination of clinical and genetic predictors with SNP-SNP interactions was included in a risk score.
Authors: Eun-Ju Lee; Daniel J Dykas; Andrew D Leavitt; Rodney M Camire; Eduard Ebberink; Pablo García de Frutos; Kavitha Gnanasambandan; Sean X Gu; James A Huntington; Steven R Lentz; Koen Mertens; Christopher R Parish; Alireza R Rezaie; Peter P Sayeski; Caroline Cromwell; Noffar Bar; Stephanie Halene; Natalia Neparidze; Terri L Parker; Adrienne J Burns; Anne Dumont; Xiaopan Yao; Cassius Iyad Ochoa Chaar; Jean M Connors; Allen E Bale; Alfred Ian Lee Journal: Blood Adv Date: 2017-06-29
Authors: Bengt Sennblad; Saonli Basu; Johanna Mazur; Pierre Suchon; Angel Martinez-Perez; Astrid van Hylckama Vlieg; Vinh Truong; Yuhuang Li; Jesper R Gådin; Weihong Tang; Vera Grossman; Hugoline G de Haan; Niklas Handin; Angela Silveira; Juan Carlos Souto; Anders Franco-Cereceda; Pierre-Emmanuel Morange; France Gagnon; Jose Manuel Soria; Per Eriksson; Anders Hamsten; Lars Maegdefessel; Frits R Rosendaal; Philipp Wild; Aaron R Folsom; David-Alexandre Trégouët; Maria Sabater-Lleal Journal: Hum Mol Genet Date: 2017-02-01 Impact factor: 6.150
Authors: Maciej M Kowalik; Piotr Trzonkowski; Magdalena Łasińska-Kowara; Andrzej Mital; Tomasz Smiatacz; Miłosz Jaguszewski Journal: Cardiol J Date: 2020-05-07 Impact factor: 2.737
Authors: S B Jensen; K Hindberg; T Solomon; E N Smith; J D Lapek; D J Gonzalez; N Latysheva; K A Frazer; S K Braekkan; J-B Hansen Journal: J Thromb Haemost Date: 2018-08-06 Impact factor: 5.824
Authors: Artitaya Lophatananon; Juliet Usher-Smith; Jackie Campbell; Joanne Warcaba; Barbora Silarova; Erika A Waters; Graham A Colditz; Kenneth R Muir Journal: Cancer Prev Res (Phila) Date: 2017-05-30
Authors: Louisa Goumidi; Florian Thibord; Kerri L Wiggins; Ruifang Li-Gao; Mickael R Brown; Astrid van Hylckama Vlieg; Joan-Carles Souto; José-Manuel Soria; Manal Ibrahim-Kosta; Noémie Saut; Delphine Daian; Robert Olaso; Philippe Amouyel; Stéphanie Debette; Anne Boland; Pascal Bailly; Alanna C Morrison; Denis O Mook-Kanamori; Jean-François Deleuze; Andrew Johnson; Paul S de Vries; Maria Sabater-Lleal; Jacques Chiaroni; Nicholas L Smith; Frits R Rosendaal; Daniel I Chasman; David-Alexandre Trégouët; Pierre-Emmanuel Morange Journal: Blood Date: 2021-04-29 Impact factor: 25.476